Miguel D. Regueiro, MD

Miguel Regueiro, MD, an expert in gastroenterology at the Cleveland Clinic, offers his choice of the most important and clinically relevant studies on Crohn's disease presented at the American College of Gastroenterology 2020 virtual annual scientific meeting.

First he looks at studies reflecting three medical approaches to treating the disease. He initially reports on the CELEST open-label extension study examining the safety and efficacy of 2 years of upadacitinib treatment.

Then he discusses the IM-UNITI long-term extension study, which took treatment with ustekinumab out to 5 years, the longest reported duration for an anti-IL-12/23 treatment.

Finally, he looks at a retrospective cohort study of the combination of vedolizumab and ustekinumab, which found that this may be an effective option for patients with refractory disease.

Switching gears, Dr Regueiro focuses on surgery-related studies, presenting an analysis of whether the type of surgical anastomosis influences long-term outcomes and opioid requirement.

Next up is a study of whether prior surgical history is the strongest predictor of postoperative Crohn's disease recurrence.

The last abstract he discusses examines whether preoperative medication exposure is associated with postoperative complications in patients undergoing ileocolic resection. The findings indicate that preoperative treatment should not be seen as a reason to delay surgery.

Miguel D. Regueiro, MD, Chairman, Professor, Department of Gastroenterology, Hepatology, and Nutrition; Vice-Chair, Digestive Disease Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Miguel D. Regueiro, MD, has disclosed the following relevant financial relationships: Serve(d) as an advisor and/or consultant for: AbbVie; Janssen; UCB; Takeda; Pfizer; Miraca Labs; Amgen; Celgene; Seres; Allergan; Genentech; Gilead; Salix; Prometheus. Received unrestricted educational grants from: AbbVie; Janssen; UCB; Pfizer; Takeda; Salix; Shire. Received research support from AbbVie; Janssen; Takeda; Pfizer.

Miguel Regueiro, MD, an expert in gastroenterology at the Cleveland Clinic, offers his choice of the most important and clinically relevant studies on Crohn's disease presented at the American College of Gastroenterology 2020 virtual annual scientific meeting.

First he looks at studies reflecting three medical approaches to treating the disease. He initially reports on the CELEST open-label extension study examining the safety and efficacy of 2 years of upadacitinib treatment.

Then he discusses the IM-UNITI long-term extension study, which took treatment with ustekinumab out to 5 years, the longest reported duration for an anti-IL-12/23 treatment.

Finally, he looks at a retrospective cohort study of the combination of vedolizumab and ustekinumab, which found that this may be an effective option for patients with refractory disease.

Switching gears, Dr Regueiro focuses on surgery-related studies, presenting an analysis of whether the type of surgical anastomosis influences long-term outcomes and opioid requirement.

Next up is a study of whether prior surgical history is the strongest predictor of postoperative Crohn's disease recurrence.

The last abstract he discusses examines whether preoperative medication exposure is associated with postoperative complications in patients undergoing ileocolic resection. The findings indicate that preoperative treatment should not be seen as a reason to delay surgery.

Miguel D. Regueiro, MD, Chairman, Professor, Department of Gastroenterology, Hepatology, and Nutrition; Vice-Chair, Digestive Disease Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Miguel D. Regueiro, MD, has disclosed the following relevant financial relationships: Serve(d) as an advisor and/or consultant for: AbbVie; Janssen; UCB; Takeda; Pfizer; Miraca Labs; Amgen; Celgene; Seres; Allergan; Genentech; Gilead; Salix; Prometheus. Received unrestricted educational grants from: AbbVie; Janssen; UCB; Pfizer; Takeda; Salix; Shire. Received research support from AbbVie; Janssen; Takeda; Pfizer.

Miguel Regueiro, MD, an expert in gastroenterology at the Cleveland Clinic, offers his choice of the most important and clinically relevant studies on Crohn's disease presented at the American College of Gastroenterology 2020 virtual annual scientific meeting.

First he looks at studies reflecting three medical approaches to treating the disease. He initially reports on the CELEST open-label extension study examining the safety and efficacy of 2 years of upadacitinib treatment.

Then he discusses the IM-UNITI long-term extension study, which took treatment with ustekinumab out to 5 years, the longest reported duration for an anti-IL-12/23 treatment.

Finally, he looks at a retrospective cohort study of the combination of vedolizumab and ustekinumab, which found that this may be an effective option for patients with refractory disease.

Switching gears, Dr Regueiro focuses on surgery-related studies, presenting an analysis of whether the type of surgical anastomosis influences long-term outcomes and opioid requirement.

Next up is a study of whether prior surgical history is the strongest predictor of postoperative Crohn's disease recurrence.

The last abstract he discusses examines whether preoperative medication exposure is associated with postoperative complications in patients undergoing ileocolic resection. The findings indicate that preoperative treatment should not be seen as a reason to delay surgery.

Miguel D. Regueiro, MD, Chairman, Professor, Department of Gastroenterology, Hepatology, and Nutrition; Vice-Chair, Digestive Disease Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Miguel D. Regueiro, MD, has disclosed the following relevant financial relationships: Serve(d) as an advisor and/or consultant for: AbbVie; Janssen; UCB; Takeda; Pfizer; Miraca Labs; Amgen; Celgene; Seres; Allergan; Genentech; Gilead; Salix; Prometheus. Received unrestricted educational grants from: AbbVie; Janssen; UCB; Pfizer; Takeda; Salix; Shire. Received research support from AbbVie; Janssen; Takeda; Pfizer.

Miguel Regueiro, MD, an expert in gastroenterology at the Cleveland Clinic, reflects on the most important and clinically relevant studies on ulcerative colitis presented at the American College of Gastroenterology 2020 virtual annual scientific meeting. He starts with four studies from the OCTAVE clinical trials program. These studies examined the efficacy and safety of tofacitinib after treatment interruption and in pregnant women, presenting almost 7 years of follow-up. Long-term follow-up remains the theme as he turns to the VISIBLE open-label extension of treatment with vedolizumab SC, where the long-term safety of the drug was confirmed and clinical remission rates were maintained out to 2 years. He reports that a post-hoc analysis of the VARSITY trial appeared to show that vedolizumab achieves greater early control vs adalimumab. Dr Regueiro next discusses the late-breaking, phase 3 True North study of ozanimod for moderate to severe ulcerative colitis before finishing up with an analysis of the long-term trends for colectomy since the turn of the century.

Miguel D. Regueiro, MD, Chairman, Professor, Department of Gastroenterology, Hepatology, and Nutrition; Vice-Chair, Digestive Disease Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Miguel D. Regueiro, MD, has disclosed the following relevant financial relationships: Serve(d) as an advisor and/or consultant for: AbbVie; Janssen; UCB; Takeda; Pfizer; Miraca Labs; Amgen; Celgene; Seres; Allergan; Genentech; Gilead; Salix; Prometheus. Received unrestricted educational grants from: AbbVie; Janssen; UCB; Pfizer; Takeda; Salix; Shire. Received research support from AbbVie; Janssen; Takeda; Pfizer.

Miguel Regueiro, MD, an expert in gastroenterology at the Cleveland Clinic, reflects on the most important and clinically relevant studies on ulcerative colitis presented at the American College of Gastroenterology 2020 virtual annual scientific meeting. He starts with four studies from the OCTAVE clinical trials program. These studies examined the efficacy and safety of tofacitinib after treatment interruption and in pregnant women, presenting almost 7 years of follow-up. Long-term follow-up remains the theme as he turns to the VISIBLE open-label extension of treatment with vedolizumab SC, where the long-term safety of the drug was confirmed and clinical remission rates were maintained out to 2 years. He reports that a post-hoc analysis of the VARSITY trial appeared to show that vedolizumab achieves greater early control vs adalimumab. Dr Regueiro next discusses the late-breaking, phase 3 True North study of ozanimod for moderate to severe ulcerative colitis before finishing up with an analysis of the long-term trends for colectomy since the turn of the century.

Miguel D. Regueiro, MD, Chairman, Professor, Department of Gastroenterology, Hepatology, and Nutrition; Vice-Chair, Digestive Disease Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Miguel D. Regueiro, MD, has disclosed the following relevant financial relationships: Serve(d) as an advisor and/or consultant for: AbbVie; Janssen; UCB; Takeda; Pfizer; Miraca Labs; Amgen; Celgene; Seres; Allergan; Genentech; Gilead; Salix; Prometheus. Received unrestricted educational grants from: AbbVie; Janssen; UCB; Pfizer; Takeda; Salix; Shire. Received research support from AbbVie; Janssen; Takeda; Pfizer.

Miguel Regueiro, MD, an expert in gastroenterology at the Cleveland Clinic, reflects on the most important and clinically relevant studies on ulcerative colitis presented at the American College of Gastroenterology 2020 virtual annual scientific meeting. He starts with four studies from the OCTAVE clinical trials program. These studies examined the efficacy and safety of tofacitinib after treatment interruption and in pregnant women, presenting almost 7 years of follow-up. Long-term follow-up remains the theme as he turns to the VISIBLE open-label extension of treatment with vedolizumab SC, where the long-term safety of the drug was confirmed and clinical remission rates were maintained out to 2 years. He reports that a post-hoc analysis of the VARSITY trial appeared to show that vedolizumab achieves greater early control vs adalimumab. Dr Regueiro next discusses the late-breaking, phase 3 True North study of ozanimod for moderate to severe ulcerative colitis before finishing up with an analysis of the long-term trends for colectomy since the turn of the century.

Miguel D. Regueiro, MD, Chairman, Professor, Department of Gastroenterology, Hepatology, and Nutrition; Vice-Chair, Digestive Disease Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Miguel D. Regueiro, MD, has disclosed the following relevant financial relationships: Serve(d) as an advisor and/or consultant for: AbbVie; Janssen; UCB; Takeda; Pfizer; Miraca Labs; Amgen; Celgene; Seres; Allergan; Genentech; Gilead; Salix; Prometheus. Received unrestricted educational grants from: AbbVie; Janssen; UCB; Pfizer; Takeda; Salix; Shire. Received research support from AbbVie; Janssen; Takeda; Pfizer.